Toxicities of CMV therapy in historic control CBT recipients
| Days 1-100∗ | |
| Foscarnet (n = 35) | Value (percentage/range) |
| Nephrotoxicity requiring dose reduction or therapy change | n = 14 patients (40%) Median creatinine increase over baseline, 1.8 fold (1.2-4.0) Median days on foscarnet, 19 (4-34) Dosing before nephrotoxicity, 7 induction, 7 maintenance |
| Ganciclovir/valganciclovir (n = 47) | Value (percentage/range) |
| G-CSF treatment (ANC <2) | n = 32 patients (68%) Median number of doses, 5 (1-22) Median days on induction dosing, 19 (0-33) Median days on maintenance dosing, 30 (0-69) |
| Days 101-180† | |
| Foscarnet (n = 8) | Value (percentage/range) |
| Nephrotoxicity requiring dose reduction or therapy change | n = 4 patients (50%) Median creatinine increase over baseline, 1.9 fold (1.6-2.3) Median days on foscarnet, 51 (25-80) Dosing before nephrotoxicity, 1 induction, 3 maintenance |
| Ganciclovir/valganciclovir (n = 40) | Value (percentage/range) |
| G-CSF treatment (ANC <2) | n = 21 patients (53%) Median number of doses, 5 (1-25) Median days on induction dosing, 0 (0-28) Median days on maintenance dosing, 48 (12-80) |
| Days 1-100∗ | |
| Foscarnet (n = 35) | Value (percentage/range) |
| Nephrotoxicity requiring dose reduction or therapy change | n = 14 patients (40%) Median creatinine increase over baseline, 1.8 fold (1.2-4.0) Median days on foscarnet, 19 (4-34) Dosing before nephrotoxicity, 7 induction, 7 maintenance |
| Ganciclovir/valganciclovir (n = 47) | Value (percentage/range) |
| G-CSF treatment (ANC <2) | n = 32 patients (68%) Median number of doses, 5 (1-22) Median days on induction dosing, 19 (0-33) Median days on maintenance dosing, 30 (0-69) |
| Days 101-180† | |
| Foscarnet (n = 8) | Value (percentage/range) |
| Nephrotoxicity requiring dose reduction or therapy change | n = 4 patients (50%) Median creatinine increase over baseline, 1.9 fold (1.6-2.3) Median days on foscarnet, 51 (25-80) Dosing before nephrotoxicity, 1 induction, 3 maintenance |
| Ganciclovir/valganciclovir (n = 40) | Value (percentage/range) |
| G-CSF treatment (ANC <2) | n = 21 patients (53%) Median number of doses, 5 (1-25) Median days on induction dosing, 0 (0-28) Median days on maintenance dosing, 48 (12-80) |